about
CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice.A higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patientsReduced red blood cell count predicts poor survival after surgery in patients with primary liver cancer.Impaired nuclear export of tumor-derived c-terminal truncated cyclin D1 mutant in ESCC cancer.SOCS3 Methylation Predicts a Poor Prognosis in HBV Infection-Related Hepatocellular Carcinoma.Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population.Decreased Expression of BNC1 and BNC2 Is Associated with Genetic or Epigenetic Regulation in Hepatocellular CarcinomaDysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis.Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region upregulating the allele-specific MYC expression in HeLa cells.Alpha fetoprotein mediates HBx induced carcinogenesis in the hepatocyte cytoplasm.DNA methylation consistency implicates the primary tumor cell origin of recurrent hepatocellular carcinoma.Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma.Alternative splicing variants of human Fbx4 disturb cyclin D1 proteolysis in human cancer.Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma.PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma.Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell.Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma.Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferationHBV T1719G mutation reduced HBV replication through mutant Enh II and HBx protein in vitro
P50
Q33765935-AEB780B3-25A7-46D4-B945-514C326A94BDQ33999798-EAB88DA5-67D6-425B-888B-4B12DCAED99CQ36009475-D457A071-7516-4114-813E-C397658C731AQ36121407-0A79A60D-7CFE-4AF1-9C33-1F1433068E43Q36184277-6A98F0A1-339D-44BB-AD8D-B38B757442B2Q36278139-913386E6-7E56-42CE-93DF-4C8BD1F8A5A0Q36666935-A112CABE-7BC3-4740-8C31-0318CDCBBCBAQ37325881-0BFA82D4-D80D-4A6B-887B-5EE7F6BC2147Q38704907-FA7FF873-1BE1-4B48-B26A-0269A20A7B05Q38890467-D8B0A898-2F97-467C-AC95-DC1AB7598499Q38894289-823C2B1A-7BC1-41A3-8852-FAC8E113F4BAQ38961539-2C2A9FBC-F556-47C8-A55F-091B96946B71Q39007490-CBDDB4F3-A975-48C1-A213-FE395C52BD6CQ39459780-279FFB08-87EC-4571-A478-4239D01B264FQ40100942-0E8CB2CD-DD51-4912-A740-F7FB00A26DF3Q41384312-C7FFB8DF-7438-40EC-8CB7-AC68D764BC77Q54214825-2DBD89DA-6398-4A6B-87B3-AA5502E63DB0Q57465004-13CEF443-7A22-4A1C-9C72-BEF29411132AQ91301260-65AD1A46-961A-4337-B1EA-6D1FD775F191
P50
description
investigador
@es
researcher
@en
name
Xiangmei Chen
@en
type
label
Xiangmei Chen
@en
prefLabel
Xiangmei Chen
@en
P31
P496
0000-0003-0302-6866